The present study aimed to compare clinical outcomes of patients with ACS and CKD treated with the new-generation DES, stratified by CKD stage, and dichotomized based on P2Y12 inhibitor type used in DAPT (ticagrelor vs. clopidogrel). The gene discussed is P2RY12; the disease is chronic kidney disease.